Pharmacological Strategies for Treatment-Resistant Depression
Summary
Treatment-resistant depression (TRD) is conventionally defined as a failure to respond to at least two adequate trials of antidepressant therapy, representing up to one-third of patients with major depressive disorder. Pharmacological management of TRD follows a staged, algorithmic approach that includes optimisation of the initial antidepressant, switching to alternatives such as serotonin-norepinephrine reuptake inhibitors or tricyclics, and augmentation with agents that target distinct neurobiological pathways. Lithium augmentation and second-generation antipsychotics have long served as cornerstone strategies by enhancing monoaminergic transmission and modulating downstream neuroplasticity. Thyroid hormones, mood stabilisers and dopaminergic agents offer additional avenues to personalise therapy. The introduction of ketamine and its S-enantiomer esketamine has reframed TRD treatment by delivering rapid amelioration via N-methyl-D-aspartate receptor blockade, although questions remain regarding optimal dosing, durability of effect and safety. Emerging pharmacotherapies harness the GABAergic system, neurosteroids and anti-inflammatory cascades, reflecting recognition of depression as a network disorder rather than solely a monoaminergic deficit. Despite incremental gains, heterogeneity in study design and patient characteristics persists, emphasising the need for biomarker-guided interventions, integration with psychological and neuromodulatory treatments, and equitable global access to novel agents.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Pharmacological Strategies for Treatment-Resistant Depression publication trend
The graph below shows the total number of articles in pharmacological strategies for treatment-resistant depression across all publications each year (not limited to Nature Index journals).
Technical terms
Treatment-resistant depression (TRD): Major depressive disorder that does not achieve remission after two or more adequate antidepressant treatments.
Augmentation: The addition of a second agent to an established antidepressant to enhance therapeutic response.
Ketamine/Esketamine: Rapid-acting NMDA receptor antagonists used to alleviate depressive symptoms within hours.
Atypical antipsychotics: Second-generation antipsychotic drugs, such as quetiapine and aripiprazole, used adjunctively in TRD.
Repetitive transcranial magnetic stimulation (rTMS): A non-invasive neurostimulation technique that modulates cortical excitability to alleviate depressive symptoms.
References
- Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. The Lancet Psychiatry (2025).
- Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. Journal of Psychopharmacology (2022).
- Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (2020).
- Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. International Journal of Molecular Sciences (2021).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.